Abstract

The genetic predisposition to chronic kidney disease (CKD) has been widely evaluated especially using the genome-wide association studies, which highlighted some novel genetic susceptibility variants in many genes, and estimated glomerular filtration rate to diagnose and stage CKD. Of these variants, rs7805747 in PRKAG2 was identified to be significantly associated with both serum creatinine and CKD with genome wide significance level. Until now, the potential mechanism by which rs7805747 affects CKD risk is still unclear. Here, we performed a functional analysis of rs7805747 variant using multiple bioinformatics software and databases. Using RegulomeDB and HaploReg (version 4.1), rs7805747 was predicated to locate in enhancer histone marks (Liver, Duodenum Mucosa, Fetal Intestine Large, Fetal Intestine Small, and Right Ventricle tissues). Using GWAS analysis in PhenoScanner, we showed that rs7805747 is not only associated with CKD, but also is significantly associated with other diseases or phenotypes. Using metabolite analysis in PhenoScanner, rs7805747 is identified to be significantly associated with not only the serum creatinine, but also with other 16 metabolites. Using eQTL analysis in PhenoScanner, rs7805747 is identified to be significantly associated with gene expression in multiple human tissues and multiple genes including PRKAG2. The gene expression analysis of PRKAG2 using 53 tissues from GTEx RNA-Seq of 8555 samples (570 donors) in GTEx showed that PRKAG2 had the highest median expression in Heart-Atrial Appendage. Using the gene expression profiles in human CKD, we further identified different expression of PRKAG2 gene in CKD cases compared with control samples. In summary, our findings provide new insight into the underlying susceptibility of PRKAG2 gene to CKD.

Highlights

  • The genetic predisposition to Chronic kidney disease (CKD) has been widely evaluated especially using the genome-wide association studies (GWAS), which highlighted some novel genetic susceptibility variants in many genes, and estimated glomerular filtration rate to diagnose and stage CKD (Pattaro et al, 2016; Wuttke and Kottgen, 2016). In these CKD risk genes, a genetic variant rs7805747 in PRKAG2 was identified to be significantly associated with both serum creatinine and CKD with genome wide significance level (Chambers et al, 2010)

  • It is reported that PRKAG2 could encode the gamma2-subunit isoform of 5 -AMP-activated protein kinase (AMPK)

  • AMPK has been identified to be a regulator of metabolism, survival, and fibrosis, by a recent integrative analysis of PRKAG2 cardiomyopathy iPS and microtissue models (Hinson et al, 2016)

Read more

Summary

Introduction

Chronic kidney disease (CKD) is a major global problem caused by the permanent loss of kidney function, and is associated with an increased risk for cardiovascular disease (Cusumano and Gonzalez Bedat, 2008; Prodjosudjadi et al, 2009; Chambers et al, 2010; Shinohara, 2010; Sherwood and McCullough, 2016; James et al, 2017; Malhotra et al, 2017; Sinha and Bagga, 2018).Functional Prediction of PRKAG2 GeneThe overall prevalence of CKD exceeds 10%, and is approximately 14% in the general population and its incidence is increasing (Almirall, 2016; Hursitoglu, 2016; Mills and He, 2016; Wuttke and Kottgen, 2016; Hedayati et al, 2017; James et al, 2017; Clark et al, 2018). The genetic predisposition to CKD has been widely evaluated especially using the genome-wide association studies (GWAS), which highlighted some novel genetic susceptibility variants in many genes, and estimated glomerular filtration rate to diagnose and stage CKD (Pattaro et al, 2016; Wuttke and Kottgen, 2016). In these CKD risk genes, a genetic variant rs7805747 in PRKAG2 was identified to be significantly associated with both serum creatinine and CKD with genome wide significance level (Chambers et al, 2010). We analyzed a whole genome case-control expression profiles in human CKD to investigate whether the susceptibility gene PRKAG2 is differently expressed in CKD cases compared with control samples

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call